Béraud et al. proinflammatory cytokine expression in a rat model of Parkinson’s disease. Eur. J. Neurosci. 18, 2731–2742. Ding, T. T., Lee, S. J., Rochet, J. C., and Lansbury, P. T. Jr. (2002). Annular alpha-synuclein protofibrils are produced when spherical protofi- brils are incubated in solution or bound to brain-derived membranes. Biochemistry 41, 10209–10217. Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nunez, G., Schnurr, M., Espevik, T., Lien, E., Fitzgerald, K. A., Rock, K. L., Moore, K. J., Wright, S. D., Hornung, V., and Latz, E. (2010). NLRP3 inflammas- omes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357–1361. Duvoisin, R. C. (1992). Overview of Parkinson’s disease. Ann. N. Y. Acad. Sci. 648, 187–193. El-Agnaf,O.M.,Salem,S.A.,Paleologou,K. E.,Cooper,L.J.,Fullwood,N.J.,Gibson, M.J.,Curran,M.D.,Court,J.A.,Mann, D. M., Ikeda, S., Cookson, M. R., Hardy, J., and Allsop, D. (2003). Alpha- synuclein implicated in Parkinson’s dis- ease is present in extracellular biological fluids,including human plasma.FASEB J. 17, 1945–1947. El Khoury, J. B., Moore, K. J., Means, T. K., Leung, J., Terada, K., Toft, M., Freeman, M. W., and Luster, A. D. (2003). CD36 mediates the innate host response to beta-amyloid. J. Exp. Med. 197, 1657–1666. Emmanouilidou, E., Melachroinou, K., Roumeliotis, T., Garbis, S. D., Ntzouni, M., Margaritis, L. H., Stefanis, L., and Vekrellis, K. (2010). Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal sur- vival. J. Neurosci. 30, 6838–6851. Feany, M. B., and Bender, W. W. (2000). A Drosophila model of Parkinson’s disease. Nature 404, 394–398. Feng, L. R., Federoff, H. J., Vicini, S., and Maguire-Zeiss, K. A. (2010). Alpha- synuclein mediates alterations in membrane conductance: a potential role for alpha-synuclein oligomers in cell vulnerability. Eur. J. Neurosci. 32, 10–17. Fink, A. L. (2006). The aggregation and fibrillation of alpha-synuclein. Acc. Chem. Res. 39, 628–634. Forno, L. S. (1996). Neuropathology of Parkinson’s disease. J. Neuropathol. Exp. Neurol. 55, 259–272. Giasson, B. I., Uryu, K., Trojanowski, J. Q., and Lee,V. M. (1999). Mutant and wild type human alpha-synucleins assem- ble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274, 7619–7622. www.frontiersin.org Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., and Golenbock, D. T. (2008). The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat. Immunol. 9, 857–865. Hamza, T. H., Zabetian, C. P., Tenesa, A., Laederach, A., Montimurro, J., Yearout, D., Kay, D. M., Doheny, K. F., Paschall, J., Pugh, E., Kusel, V. I., Collura, R., Roberts, J., Griffith, A., Samii, A., Scott, W. K., Nutt, J., Factor, S.A., and Payami, H. (2010). Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease. Nat. Genet. 42, 781–785. Hashimoto, M., Hsu, L. J., Xia, Y., Takeda, A., Sisk,A., Sundsmo, M., and Masliah, E. (1999). Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 10, 717–721. He, Y., Appel, S., and Le, W. (2001). Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res. 909, 187–193. Henn, A., Lund, S., Hedtjarn, M., Schrattenholz, A., Porzgen, P., and Leist, M. (2009). The suitability of BV2 cells as alternative model system for primary microglia cultures or for animal experiments examining brain inflammation. ALTEX 26, 83–94. Horvath, R. J., Nutile-Mcmenemy, N., Alkaitis, M. S., and Deleo, J. A. (2008). Differential migration, LPS-induced cytokine, chemokine, and NO expres- sion in immortalized BV-2 and HAPI cell lines and primary microglial cul- tures. J. Neurochem. 107, 557–569. Hsu, L. J., Sagara, Y., Arroyo, A., Rockenstein, E., Sisk, A., Mallory, M., Wong, J., Takenouchi, T., Hashimoto, M., and Masliah, E. (2000). Alpha- synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 157, 401–410. Hu, S., Chao, C. C., Khanna, K.V., Gekker, G., Peterson, P. K., and Molitor, T. W. (1996). Cytokine and free radical pro- duction by porcine microglia. Clin. Immunol. Immunopathol. 78, 93–96. Jana, M., Palencia, C. A., and Pahan, K. (2008). Fibrillar amyloid-beta pep- tides activate microglia via TLR2: implications for Alzheimer’s disease. J. Immunol. 181, 7254–7262. Jang, A., Lee, H. J., Suk, J. E., Jung, J. W., Kim, K. P., and Lee, S. J. (2010). Non- classical exocytosis of alpha-synuclein is sensitive to folding states and pro- moted under stress conditions. J. Neurochem. 113, 1263–1274. Jin, J. J., Kim, H. D., Maxwell, J. A., Li, L., and Fukuchi, K. (2008). Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer’s disease. J. Neuroinflammation 5, 23. Jin, M. S., and Lee, J. O. (2008). Structures of the toll-like receptor family and its ligand complexes. Immunity 29, 182–191. Kensler, T. W., Wakabayashi, N., and Biswal, S. (2007). Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 47, 89–116. Kim,Y. H., Lussier, S., Rane,A., Choi, S.W., and Andersen, J. K. (2011). Inducible dopaminergic glutathione depletion in an alpha-synuclein transgenic mouse model results in age-related olfactory dysfunction. Neuroscience 172, 379–386. Kim,Y. S., and Joh, T. H. (2006). Microglia, major player in the brain inflamma- tion: their roles in the pathogenesis of Parkinson’s disease. Exp. Mol. Med. 38, 333–347. Kitamura,Y., Furukawa, M., Matsuoka,Y., Tooyama, I., Kimura, H., Nomura, Y., and Taniguchi, T. (1998a). In vitro and in vivo induction of heme oxygenase-1 in rat glial cells: possible involvement of nitric oxide production from inducible nitric oxide synthase. Glia 22, 138–148. Kitamura, Y., Matsuoka, Y., Nomura, Y., and Taniguchi, T. (1998b). Induction of inducible nitric oxide synthase and heme oxygenase-1 in rat glial cells. Life Sci. 62, 1717–1721. Knott, C., Stern, G., and Wilkin, G. P. (2000). Inflammatory regula- tors in Parkinson’s disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2.Mol. Cell. Neurosci. 16,724–739. Ko hut n i ck a , M . , Le w a n dow s k a , E., Kurkowska-Jastrzebska, I., Czlonkowski, A., and Czlonkowska, A. (1998). Microglial and astro- cytic involvement in a murine model of Parkinson’s disease induced by 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology 39, 167–180. Kowall, N. W., Hantraye, P., Brouillet, E., Beal, M. F., Mckee, A. C., and Ferrante, R. J. (2000). MPTP induces alpha- synuclein aggregation in the substan- tia nigra of baboons. Neuroreport 11, 211–213. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, J. T., Schols, L., and Riess, O. (1998). Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat. Genet. 18, 106–108. α-Synuclein and TLRs Lee, E. J.,Woo, M. S., Moon, P. G., Baek, M. C., Choi, I.Y., Kim,W. K., Junn, E., and Kim, H. S. (2010). Alpha-synuclein activates microglia by inducing the expressions of matrix metallopro- teinases and the subsequent activa- tion of protease-activated receptor-1. J. Immunol. 185, 615–623. Lee, F. J., Liu, F., Pristupa, Z. B., and Niznik, H. B. (2001). Direct binding and func- tional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 15, 916–926. Lee, H. J., Patel, S., and Lee, S. J. (2005). Intravesicular localization and exo- cytosis of alpha-synuclein and its aggregates. J. Neurosci. 25, 6016–6024. Lee., H. J., Suk., J. E., Bae, E. J., Lee, J. H., Paik, S. R. and Lee, S. J. (2008). Assembly-dependent endocytosis and clearance of extracellular alpha- synuclein. Int. J. Biochem. Cell Biol. 40, 1835–1849. Lee, S. J., and Lee, S. (2002). Toll-like receptors and inflammation in the CNS. Curr. Drug Targets Inflamm. Allergy 1, 181–191. LeVine, H. III. (1999). Quantification of beta-sheet amyloid fibril structures with thioflavin T. Meth. Enzymol. 309, 274–284. Liu, B. (2006). Modulation of micro- glial pro-inflammatory and neu- rotoxic activity for the treatment of Parkinson’s disease. AAPS J. 8, E606–E621. Maguire-Zeiss, K. A., Wang, C. I.,Yehling, E., Sullivan, M. A., Short, D. W., Su, X., Gouzer, G., Henricksen, L. A., Wuertzer, C. A., and Federoff, H. J. (2006). Identification of human alpha-synuclein specific single chain antibodies. Biochem. Biophys. Res. Commun. 349, 1198–1205. Masliah, E., Rockenstein, E.,Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., and Mucke, L. (2000). Dopaminergic loss and inclusion body formation in alpha- synuclein mice: implications for neu- rodegenerative disorders. Science 287, 1265–1269. McLean, P. J., Kawamata, H., Ribich, S., and Hyman, B. T. (2000). Membrane association and protein conforma- tion of alpha-synuclein in intact neurons. Effect of Parkinson’s disease- linked mutations. J. Biol. Chem. 275, 8812–8816. Moi, P., Chan, K., Asunis, I., Cao, A., and Kan,Y. W. (1994). Isolation of NF-E2- related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc. Natl. Acad. Sci. U.S.A. 91, 9926–9930. June 2011 | Volume 5 | Article 80 | 9